Dynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting - Seite 2

Abstract:		5741
Category:		Clinical Research
Date/Time:		Tuesday, Apr 4, 1:00 p.m. to 5:00 p.m. ET
Location:		Poster section 30; Board number 12

Intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates more effective immunity in both injected and un-injected tumor sites compared to subcutaneous administration

Abstract:		6000
Category:		Immunology
Date/Time:		Wednesday, Apr 5, 8:00 a.m. to 12:00 p.m.
Location:		Poster section 24; Board number 28

About SD-101

SD-101 is Dynavax's proprietary, second-generation, TLR9 agonist CpG-C class oligodeoxynucleotide. SD-101 is being studied for its multiple anti-tumor activities in innate immune cells and activation of plasmacytoid dendritic cells to stimulate T cells specific for antigens released from dying tumor cells. TLR9 agonists such as SD-101 enhance T and B cell responses and provide potent Type 1 interferon induction and maturation of plasmacytoid dendritic cells to antigen-presenting cells. SD-101 is being evaluated in several Phase 1/2 oncology studies to assess its safety and activity.